CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
rosiglitazone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00424762
NCT00424762Phase 4Completed
CompareCT.gov

Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride

University of Texas Southwestern Medical Center·interventional·Posted Jan 22, 2007·Updated Apr 4, 2012

In Brief

A Phase 4 clinical trial evaluating rosiglitazone and placebo for Diabetes Mellitus, Type 2. Completed, enrolled 150 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if rosiglitazone treatment improves integrated cardiovascular performance in patients at risk for congestive heart failure. A second aim of this study is to determine if treatment with rosiglitazone decreases intracellular (ectopic) triglyceride (TG) deposition in cardiomyocytes using nuclear magnetic resonance (NMR) techniques, and how changes in intra-myocardial lipid content relate to changes in cardiac structure and function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsGlaxoSmithKline, Abbott RDx Cardiometabolic

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 22, 2007
Enrollment StartFeb 1, 2005
Primary CompletionApr 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.4 years ago

Interventions

rosiglitazonedrug

6 months of treatment of blinded study drug

placebodrug

blinded treatment with matching placebo